Reviewing the top presentations from ASCO GU 2024, including the phase III GETUG-AFU-18 study, CONTACT-02, and more.
The Uromigos: ASCO GU
Hear Thomas Powles, MD, and Brian Rini, MD, FASCO, discuss research and news from the ASCO GU Symposium.
Advertisement
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
Dr. Bergerot describes her modifications of existing quality of life models, and Tom explains LITESPARK-005's QoL data.
Dr. Pedro Barata gives an overview of the CheckMate 914 trial on adjuvant nivolumab plus ipilimumab for localized RCC.
Andrea Apolo, MD, discusses the phase III AMBASSADOR study that investigated adjuvant pembrolizumab against observation.
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer.
The Uromigos discuss the presentations to look out for at this year's ASCO Genitourinary Cancers Symposium.
Expert Interviews
More ASCO GU Coverage
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Petros Grivas, MD, PhD, highlights the practice-changing studies that have come out of the ASCO GU 2023 Symposium.
Michael Atkins, MD, discusses TFS outcomes from the phase II study and argues for immunotherapy in favorable-risk patients.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.